GG
FOLD

GCM Grosvenor’s Amicus Therapeutics FOLD Stock Holding History

GCM Grosvenor’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$13.6M Buy
905,162
+806,613
+818% +$12.3M 3.31% 9
2017
Q4 		$1.42M Buy
+98,549
New +$1.35M 0.54% 11
2017
Q3 		– Sell
-601,411
Closed -$6.06M – 10
2017
Q2 		$6.06M Sell
601,411
-1,029,194
-63% -$8.28M 3.43% 8
2017
Q1 		$11.6M Buy
+1,630,605
New +$10.3M 10.26% 5

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GCM Grosvenor's FOLD Position: Q1 2018 in Review

GCM Grosvenor increased its Amicus Therapeutics (FOLD) stake by 818% in Q1 2018, buying an estimated $12.3M and bringing the position to 905,162 shares worth $13.6M. The position accounts for 3.31% of the portfolio, ranked #9.

GCM Grosvenor first reported a position in FOLD in Q1 2017 and has held it in 4 quarters since. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2018.

  • GCM Grosvenor held 905,162 shares of Amicus Therapeutics worth $13.6M as of Q1 2018.
  • GCM Grosvenor bought 806,613 Amicus Therapeutics shares in Q1 2018, an estimated $12.3M.
  • Amicus Therapeutics made up 3.31% of GCM Grosvenor's portfolio in Q1 2018, its #9 holding.
  • GCM Grosvenor first reported a position in Amicus Therapeutics in Q1 2017 and has held it in 4 quarters since.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2018.

Based on GCM Grosvenor's 13F filing for Q1 2018, filed 15 May 2018.